Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery
Read More: Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug DiscoveryVariational AI, a generative AI drug discovery company, announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply Variational AI’s Enki™ platform to design and optimize novel small molecule candidates against two undisclosed… Read More about Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery
Our Latest News
Featured
Blog & Press
Variational AI and Rakovina Therapeutics Expand Collaboration to Accelerate Next-Generation ATR Inhibitors
Variational AI and Rakovina Therapeutics expand their collaboration to advance Rakovina’s kt-5000 series of ATR inhibitors Read More about Variational AI and Rakovina Therapeutics Expand Collaboration to Accelerate Next-Generation ATR Inhibitors
Update: Advancing CNS-penetrant ATR inhibitors with Enki™
Building on their initial hit series, Variational AI and Rakovina Therapeutics share promising new results on ATR inhibitors generated with Enki. The latest findings reveal compounds that balance potency, selectivity,… Read More about Update: Advancing CNS-penetrant ATR inhibitors with Enki™
Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery
Variational AI, a generative AI drug discovery company, announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply Variational AI’s Enki™ platform to… Read More about Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery
Variational AI & Life Chemicals join forces to discover selective dual EGFR/FGFR1 inhibitors using generative AI
Following their successful 2022 collaboration, which targeted the SARS-CoV-2 main protease, Variational AI and Life Chemicals have partnered for a second time to discover de novo generated selective dual EGFR/FGFR1… Read More about Variational AI & Life Chemicals join forces to discover selective dual EGFR/FGFR1 inhibitors using generative AI
Variational AI Joins Agora Open Science Trust to Advance PRMT6 Inhibitors for SBMA
Variational AI is proud to announce its participation in a new open science drug discovery initiative led by Agora Open Science Trust. The project is focused on optimizing the potency… Read More about Variational AI Joins Agora Open Science Trust to Advance PRMT6 Inhibitors for SBMA
Variational AI Named “Emerging Company of the Year – Biotech” by Life Sciences BC
Variational AI is proud to announce that it has been named Emerging Company of the Year – Biotech by Life Sciences BC. This award highlights Variational AI’s innovation in developing… Read More about Variational AI Named “Emerging Company of the Year – Biotech” by Life Sciences BC
Upcoming Events
San DiegoVariational AI at Drug Discovery Chemistry 2026
Variational AI will participate in Drug Discovery Chemistry 2026, a premier conference for scientists focused on the discovery and optimization of small-molecule therapeutics. The event brings together medicinal, biophysical, and computational chemists from pharmaceutical companies,… Learn More about Variational AI at Drug Discovery Chemistry 2026
VancouverVariational AI to speak at ALL IN Talks West
Variational AI will participate in ALL IN Talks West, an event bringing together researchers, industry leaders, builders, and decision-makers focused on the practical deployment of artificial intelligence systems in real-world environments. “From World-Class Research to… Learn More about Variational AI to speak at ALL IN Talks West
TorontoVariational AI to Participate in the Bloom Burton Healthcare Investor Conference
Variational AI will participate in the Bloom Burton & Co. Healthcare Investor Conference (BBHIC), one of North America’s leading gatherings for healthcare investors and emerging life sciences companies. Meet with Variational AI Handol Kim, Co-Founder… Learn More about Variational AI to Participate in the Bloom Burton Healthcare Investor Conference
- Toronto
Variational AI to Participate in the MaRS Impact Health Summit
Variational AI will participate in MaRS Impact Health, a flagship health innovation event hosted by MaRS Discovery District that brings together entrepreneurs, investors, scientists, clinicians, and policymakers working to advance the future of healthcare. Meet… Learn More about Variational AI to Participate in the MaRS Impact Health Summit
BostonVariational AI to Present at PBSS Event on AI and ML in Drug Discovery
Variational AI will participate in the upcoming Boston Pharmaceutical & Bioscience Society (PBSS) event, “Artificial Intelligence and Machine Learning: Shaping the Future of Therapeutic Drug Discovery, Development, and Manufacturing,” taking place April 28, 2026, in… Learn More about Variational AI to Present at PBSS Event on AI and ML in Drug Discovery
- San Diego
Variational AI at BIO International Convention 2026
Variational AI will be attending BIO International Convention 2026 in San Diego. We’ll be onsite for partnering meetings to connect with pharma and biotech teams interested in accelerating small-molecule programs with generative AI—especially where speed,… Learn More about Variational AI at BIO International Convention 2026
Media & Resources
How Generative AI Helped Design a Brain-Penetrant Cancer Drug Candidate (Webinar Recording)
From Handshake to Breakthrough: How Generative AI Helped Design a Brain-Penetrant Cancer Drug Candidate (Webinar Recording) In this 60-minute fireside chat, Rakovina Therapeutics and Variational AI share the story behind… Read More about How Generative AI Helped Design a Brain-Penetrant Cancer Drug Candidate (Webinar Recording)
What’s with RWE Podcast: Generative AI for Drug Discovery
Handol Kim, CEO of Variational AI, shares insights on the growing role of generative AI in pharmaceutical research. The discussion highlights how advanced machine learning approaches can help researchers explore… Read More about What’s with RWE Podcast: Generative AI for Drug Discovery
Variational AI – Emerging Company of the Year
27th Annual LSBC Award – Awards Video – Emerging Company of the Year -Biotech: Variational AI Read More about Variational AI – Emerging Company of the Year
Building a Foundation Model for Drug Discovery
In this interview, Jason Rolfe, Co-Founder and CTO of Variational AI, discusses how foundation models are transforming small-molecule drug discovery. The conversation explores how generative AI platforms like Enki™ can… Read More about Building a Foundation Model for Drug Discovery